Addressing the silent pandemic: the UK’s response to AMR

Addressing the silent pandemic Addressing the silent pandemic: the UK’s response to AMR Patrick King Hashmath Hassan Policy roundtable summary Addressing the silent pandemic: the UK’s response to AMR Reform was delighted to host a policy roundtable on the practical steps that will be needed in the new 2024-2029 AMR Action Plan to stem the rise of drug resistance. [...] Though confidence in immunisation programmes is generally very high in the UK, In addition to effective stewardship, and central uptake rates have been falling for the past to achieving lower antibiotic prescribing in the decade, and there are communities for which long-run, is improving diagnostic capability in uptake is markedly lower – putting them at primary and secondary care. [...] Participants reflected that, while it is easier to communicate the need for vaccines Diagnostics against life-threatening infections, or the importance of protecting immunocompromised There is a significant gap between primary and patients, it can be more difficult to communicate secondary care in how frequently point-of-care the need for vaccines to protect against a number diagnostic tools are u. [...] benefits from diagnostics accrue to the wider Participants referred to the potential for public health system rather than any individual practice awareness campaigns, lessons in schools, and – meaning some GPs see diagnostic tools as a public forums with community leaders to be used more costly and time-consuming alternative to in conjunction to increase vaccine uptake. [...] The traditional and research groups to commit to R&D – approach to drug development is to target particularly as no new class of antibiotic has been specific pathogens.